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   Dermatitis Herpetiformis: An Introduction 
Dermatitis herpetiformis (DH) is a chronic autoimmune disease that manifests on the 
skin (Bolotin & Petronic-Rosic, 2011, p. 1017). DH presents with erythematous 
papules that often have vesicles (p. 1020). The lesions are intensely pruritic, so much 
so that they are often excoriated by the time a patient is evaluated by a physician. 
They have a distinct presentation erupting symmetrically on the extensor surfaces of 
the upper and lower extremities. Locations include the elbows, knees, scalp, and 
buttocks (p. 1020).  
 
DH is considered an extra-intestinal manifestation of celiac disease (CD) 
(Krishnareddy, 2013). DH and CD are both autoimmune gluten sensitivities that are 
mediated by immunoglobulin A (IgA) (Bolotin & Petronic-Rosic, 2011, p. 1017). Key 
differences include the main autoantigens involved. DH involves epidermal 
transglutaminase (eTG) while CD involves tissue transglutaminase (tTG). A definitive 
diagnosis of DH is made with a biopsy taken from perilesional skin that is positive for 
granular deposition of IgA in the dermal papillae and the basement membrane under 
direct immunofluorescence (p. 1020).  A diagnosis of CD begins with serologic testing 
(Autodore, Verma, & Gupta, 2012, p. 272). . If those tests are positive for CD related 
immunoglobulins, a endoscopic biopsy of the duodenum is in order. If CD is present, 
the biopsies will show villous atrophy. Both diseases are associated with human 
leukocyte antigen (HLA) (Bolotin & Petronic-Rosic, 2011, p. 1019). Genetic tests show 
HLA-DQ2 and HLA-DQ8 in effected carriers. Both diseases are treated with a life-long 
gluten free diet (GFD). DH treatment may include the use of the antibiotic dapsone 
for an extended period of time.  
  
DH is of particular importance to myself because I have struggled with finding a 
diagnosis for the symptoms I have been experiencing over the past few years. DH was 
first considered a possibility for me after I presented to a dermatologist for the 
second time in a matter of months with incredibly pruritic lesions. No matter what I 
did they would not go away. I ended up seeing a gastroenterologist, but my 
neurologist has been the most helpful in my journey. She has celiac disease and 
completed the serologic testing needed for diagnosis. I tested positive for the genes 
involved with CD, but the immunologic testing was negative. She recommended I 
start a GFD to alleviate they various symptoms I was having that included others that 
just the skin presentation. After going back and forth with the necessity of a GFD 
when I did not have positive serologic studies, I realized that my thinking was much 
clearer when following the diet. I committed to following it. I did however continue to 
break out with the pruritic lesions. After multiple courses of prednisone I again 
returned to the dermatologist. He said that he believed DH is the correct diagnosis.  
After some more research I found that serologic studies are not always positive in 
those with DH, but it is still a manifestation of CD.  
 
There is an abundance of literature on CD.  It is my hope that through this project 
others practitioners will be provided with information on a disease they might not 
have otherwise heard of.  
The main sign that accompanies DH is 
the eruption of intensely pruritic 
papulovesical lesions that typically 
present bilaterally on the elbows, 
knees, buttocks, neck, and scalp 
(Criado et al., 2012). They may appear 
on the upper back, abdomen, groin, 
and face as well. The lesions are small 
blisters that resemble those that are 
caused by the herpes simplex virus. By 
the time a patient seeks evaluation by 
a care provider, the lesions have often 
been scratched so much as to cause 
erosions, excoriation, and or crusted 
papules (Junkins-Hopkins, 2010). The 
surrounding area may have erythema 
and or urticarial plaques. Patients may 
have areas of hyperpigmentation from 
previous outbreaks (Bonciani et al., 
2012). The breakouts are of a chronic 
nature and will have periods of flare 
ups and remission. The periods of 
remission do not typically last long 
than several weeks (Criado et al., 
2012). The hallmark symptom that 
patients with DH report is extremely 
intense itching. They may report 
experiencing the itching, a burning 
and or a stinging sensation up to 12 
hours prior to eruptions on the skin.  
The pathophysiology of DH involves genetics, environment, and an immune 
response. Nearly all patients with DH are carriers of either the human leukocyte 
antigen (HLA) DQ2 or HLA DQ8 alleles (Bonciani et el., 2012). These are the same 
alleles the are present in patients with CD. The HLA DQ2 is the more commonly 
carried allele. The presences of one of these alleles is so strongly associated with DH 
and CD that the sensitivity of the test is nearly 100%. The absence of either allele 
nearly excludes a diagnosis of either disease. Studies performed using monozygotic 
twins and analysis of the incidence of the alleles among first-degree relatives shows 
the strong genetics factors are at play in the development of DH and CD (Bolotin &  
Petronic-Rosic, 2010).  
 
The environment required to induce the reaction involved with DH is a diet 
containing gluten. Gluten is a protein composite found in wheat, rye, and barley ( 
Bonciani et al., 2012). Gliadin, a component of gluten, is indigestible, and an alcohol-
soluble protein that leads to the immune reaction involved in DH and CD.  
The immune response in DH is seen in biopsies of active lesions, as well as 
perilesional skin (Bonciani et al., 2012). A biopsy positive for granular IgA in the 
dermal papillae and may also be present in the basement membrane (Junkins-
Hopkins, 2010).  It is believed to be IgA that helps neutrophils infiltrate the papillae 
and the basement membrane (Nakajima, 2012). Immunofluorescence studies are 
used for definitive diagnosis and to rule out similar presenting disorders of the 
skin such as bullous dermatosis (Bolotin & Petronic-Rosic, 2011).  
 
Serum studies can be used to help in the diagnostic process. They  evaluate for the 
presence of circulating IgA antibodies to endomysium (Bolotin & Petronic-Rosic, 
2011). The IgA antibodies found in DH patients are specific for epidermal-specific 
transglutaminase (TG), known as anti-epidermal transglutaminase (eTG). Serum 
studies measuring anti-eTG are 95% sensitive for DH.  
 
The immune response to gluten in the DH patient is evidenced by the inflammatory 
infiltrate composed of neutrophils on the dermal papillary tips seen on biopsy, as 
well as IgA deposits (Bonciani et al., 2012).  Lesions are composed are also 
composed of eosinophils and fibrin which help to form microabscesses. The 
inflammation triggering T cells are also present on the lesions and perilesional 
skin, further evidence of immune response.  
The pathophysiology of DH has 
significant implications for nurses that 
diagnose and care for these patients. 
Being able to provide an accurate 
diagnosis is the first step. Prescribing 
treatment and educating patients on 
the intricacies of a gluten free diet and 
the medication options available can 
be a involved process. The importance 
of a life-long gluten free diet must be 
communicated. Poor compliance has 
been associate with low levels of 
information on the GFD (Fasano, 
2012).  Even if remission is seen with 
the adjunct of medication, the diet is 
the only way to keep the flares from 
returning.  
 
Currently the main pharmacologic 
treatment of CD is dapsone. Even 
following a strict GFD, IgA deposits 
within the skin are seen up to several 
years after its initiation (Bolotin & 
Petronic-Rosic, 2011). Dapsone has 
both anti-inflammatory and 
antibacterial properties that inhibit the 
recruitment of neutrophils. Dapsone 
therapy helps to resolve the active 
lesions within days of beginning 
treatment. There are drawbacks to its 
use, including methemoglobinemia 
and agranulocytosis. These are serious 
conditions that require frequent 
monitoring. If the patient is unable to 
tolerate dapsone therapy, sulfasalzine 
or sulfamethoxypridazine may be 
used.  
 
DH is a disease that can present like 
many other skin diseases. To be able to 
accurately diagnose it can make an 
incredible difference in a patient’s life.  
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